ClinicalTrials.gg
CompletedNCT01530659Updated Feb 14, 2023Results posted

Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa

A Phase 2 interventional study of NT-501 and Sham in Retinitis Pigmentosa, Usher Syndrome Type 2 and Usher Syndrome Type 3, sponsored by Neurotech Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-02-14.

Primary conditionUsher SyndromesRegistry: Retinitis PigmentosaReclassifiedWhy we changed it
Registry
Retinitis Pigmentosa — the first condition term the registry derived for this study.
ClinicalTrials.gg
Usher Syndromes
Why
  1. The study's listed conditions name Usher Syndromes, a narrower term within Retinitis Pigmentosa.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Neurotech Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Usher Syndromes with a site in United States — 5 open to participants now, 8 under way, 2 of them phase 3. Usher Syndromes · United States.

Enrollment
7th of 13
22 · median 22
Started
2012
with 1 other
Phase 2
4 of 20
none open now
Registered
7th of 20
by date

Among the 20 studies in Usher Syndromes with a site in United States, this one is the 7th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2012, is one of 4 in phase 2, and was the 7th registered.

Usher Syndromes

33 studies on the registry are indexed under Usher Syndromes; 13 are open to participants now.

Browse Usher Syndromes studies →

Open to participants now

5 of the 20 studies in Usher Syndromes with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Usher Syndromes studies recruiting now, 7 (70%) set no upper age limit and 2 (20%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Usher Syndromes with a site in United States, or all of them as a file.
02

Study summary

This clinical trial is a single-site, 30 patient study for participants who have early stage retinitis pigmentosa, or Usher syndrome (type 2 or 3). Funding Source - FDA OOPD and Foundation Fighting Blindness.

Read the detailed description

This clinical trial is a prospective, randomized, double-masked, sham-controlled trial of 30 study participants who have early-stage retinitis pigmentosa, or Usher syndrome (type 2 or 3). The trial will be conducted at the University of California, San Francisco. Individuals with these diseases experience gradually worsening vision that ultimately may lead to blindness due to a genetic condition in which specialized cells in the eye's retina called photoreceptor cells cease functioning and/or die. The study is intended to use a relatively new, non-invasive technology called AOSLO (adaptive optics scanning laser ophthalmoscopy) in combination with a routine standard of care measurement called sdOCT (Spectral Domain Optical Coherence Tomography) to demonstrate that when a device that secretes an investigational drug called CNTF (Ciliary Neurotrophic Factor) is surgically placed in the patient's eye, one type of photoreceptor called "cone photoreceptors" is preserved such that the gradual loss of vision is halted.

03

Conditions studied

  • Retinitis Pigmentosa
  • Usher Syndrome Type 2
  • Usher Syndrome Type 3

Browse trials for

Keywords

  • Retinitis pigmentosa
  • Usher syndrome type 2
  • Usher syndrome type 3
  • Cone photoreceptor
  • Vision
  • Blind
04

In context

Usher Syndromes Reclassified

33 studies on the registry are indexed under Usher Syndromes; 13 are open to participants now.

This study's enrollment of 22 is below the median of 39 across 18 interventional studies indexed under Usher Syndromes.

Browse Usher Syndromes studies →

Lead sponsor

Neurotech Pharmaceuticals is the lead sponsor of 13 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Compared within Usher Syndromes, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Retinitis Pigmentosa. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be between 18 and 55 years of age.
  2. Participant must have a diagnosis of retinitis pigmentosa or Usher Syndrome type 2 or 3 (without profound deafness or cochlear implants).
  3. Participant must understand and sign the protocol . If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.
  4. Best-corrected visual acuity must be no worse than 20/63 (at least 59 letters).
  5. Participants must have clear natural lenses.
  6. Participants must have less than 6 diopters myopia.
  7. Participants must be medically able to undergo ophthalmic surgery for the NT-501 device insertion and able to undergo all assessments and tests associated with the protocol.
  8. Females of (women with last menses \<1 year prior to screening) must agree to use an effective form of from study onset until they complete the study.
  9. Participants must have reproducible baseline AOSLO image at 2 baseline imaging sessions with quality suitable to identify a minimum of 7 regions of interest (ROIs) at which reliable cone spacing and/or density measures can be made over the central 5.7 degrees.
  10. Participants must have interocular symmetry of disease severity as measured by cone spacing, with a difference of less than 2 standard deviations in average cone spacing z-scores at the selected ROIs between the 2 eyes.
  11. Participant's clinical diagnosis must be consistent with retinal degeneration in the set of retinitis pigmentosa (RP) dystrophies.

Exclusion criteria

Exclusion Criteria:

  1. Participant is medically unable to comply with study procedures or follow-up visits.
  2. Participant who has any of the following lens opacities: cortical opacity > standard 3, posterior subcapsular opacity > standard 3, or a nuclear opacity > standard 3 as measured on the AREDS clinical lens grading system; or participant is pseudophakic or aphakic.
  3. Participant has history of corneal opacification or lack of optical clarity.
  4. Participant has undergone LASIK surgery or other refractive surgery for either eye.
  5. Participant has nystagmus.
  6. Participant has greater than 6 diopters myopia.
  7. Participant has cystoid macular edema with cysts present within 4 degrees of the foveal center that prevent acquisition of at least 7 regions of interest with clear images of cone photoreceptors.
  8. Participant has fewer than 7 regions of interest (ROIs) present on 2 baseline AOSLO image montages.
  9. Participant has retinal vascular disease such as diabetic retinopathy or prior retinal vascular occlusive disease.
  10. Participant has chronic requirement (e.g., ≥4 weeks at a time) for ocular medications or has disease(s) that in the judgment of the examining physician are vision threatening, toxic to the lens, retina, or optic nerve or may affect the primary outcome.
  11. Participant has a requirement of acyclovir and/or related products during study duration. To be eligible for this study, the participant must discontinue use of these products prior to enrollment and must not continue with the products until after they have completed the study.
  12. Participant is receiving systemic or other medications.
  13. Participant is currently participating in or has participated in any other clinical trial of a drug by ocular or systemic administration within the last 6 months.
  14. Participant has previous exposure to an intra-ocular device or implant into the eye (excluding intra-ocular lens).
  15. Participant has uveitis or other retinal inflammatory disease.
  16. Participant has a history of myocardial infarction within the last 12 months.
  17. Participant is pregnant or lactating.
  18. Participant is considered immunodeficient or has a known history of . A laboratory test for HIV will be performed, and a positive result is also an exclusion criterion.
  19. Participant with a history of ocular herpes zoster.
  20. Participant is on chemotherapy.
  21. Participant has a history of , except study participant with cancer treated successfully ≥5 years prior to inclusion in the trial.
  22. Participant with severe hearing disabilities in both ears.
  23. Participant who has been diagnosed and treated for amblyopia as an infant.
  24. Participant who, in the opinion of the study doctor, will not be a good study subject.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    NT-501

    Encapsulated cell therapy that delivers ciliary neurotrophic factor to the retina

    Drug: NT-501

  • Sham comparator
    Sham

    Sham surgery

    Procedure: Sham

Interventions

  • DrugNT-501

    Study participants will undergo surgery to have an NT-501 Encapsulated Cell Therapy implant placed into the study eye.

    Also known as: CNTF, Encapsulated Cell Therapy, ECT

  • ProcedureSham

    Non-penetrating sham procedure to mimic implant procedure in the other eye.

07

What researchers measure

Primary outcomes

  1. Mean Change in Cone Spacing in Arcminutes (Z Score) of 2 Baseline Values Were Compared With Measurements Obtained at Post-op Month 36

    Average of cone spacing (nearest neighbor distance) at all regions of interest with at least 50 contiguous unambiguous cones identified over the central 5.7 degrees of the macula using confocal AOSLO at two baseline visits within each eye. Cone spacing measures were converted to Z scores based on normal mean values at similar distances from the fovea from a database of 27 age-similar normal eyes. The mean of 2 baseline cone spacing Z-score values were subtracted from the cone spacing Z score values obtained at post-op month 36 A Z-score of 0 represents the mean cone spacing value at the distance from the fovea measured from 27 healthy subjects. A Z-score greater than +2 represents an abnormally increased cone spacing value at the distance from the fovea where the measurement was performed. This suggests fewer cones are present than normal at that location.

    Time frame: Post-op Month 36

Secondary outcomes

  1. Difference in logMAR Visual Acuity Change Between CNTF- and Sham Treated Eyes

    Difference in change in logMAR visual acuity between NT-501 and contralateral sham-treated eyes. Change in visual acuity was measured based on the number of letters read on a vision chart using a standard protocol. The log of the mean angle of resolution (logMAR) was used to describe the size of the smallest letters that the patient could read. A logMAR value of 0.00 corresponds to visual acuity of 20/20, a logMAR value of 0.3 corresponds to visual acuity of 20/40, a logMAR value of 0.7 corresponds to visual acuity of 20/100, and a logMAR value of 1.00 corresponds to visual acuity of 20/200.

    Time frame: Post-op Month 36

08

Results

Posted Feb 14, 2023

Participant flow

Eligible subjects were \>18 years old with retinitis pigmentosa or Usher syndrome and adaptive optics scanning laser ophthalmoscopy (AOSLO) images in each eye with at least 7 regions having at least 50 contiguous unambiguous cones in the central 5.7 degrees of the macula at 2 baseline visits. Exclusion criteria included visual acuity worse than 20/40, lens opacity, \> -6.00 D myopia, nystagmus, cystoid macular edema, retinal vascular disease, unstable fixation, and severe hearing loss.

Participant flow — Overall Study
MilestoneNT-501 ImplantSham Surgery
Started2222
Completed2222
Not completed00

Outcome measures

PrimaryMean Change in Cone Spacing in Arcminutes (Z Score) of 2 Baseline Values Were Compared With Measurements Obtained at Post-op Month 36

Average of cone spacing (nearest neighbor distance) at all regions of interest with at least 50 contiguous unambiguous cones identified over the central 5.7 degrees of the macula using confocal AOSLO at two baseline visits within each eye. Cone spacing measures were converted to Z scores based on normal mean values at similar distances from the fovea from a database of 27 age-similar normal eyes. The mean of 2 baseline cone spacing Z-score values were subtracted from the cone spacing Z score values obtained at post-op month 36 A Z-score of 0 represents the mean cone spacing value at the distance from the fovea measured from 27 healthy subjects. A Z-score greater than +2 represents an abnormally increased cone spacing value at the distance from the fovea where the measurement was performed. This suggests fewer cones are present than normal at that location.

Time frame:
Post-op Month 36
Reported as:
Mean · Difference in change in Z score
Mean Change in Cone Spacing in Arcminutes (Z Score) of 2 Baseline Values Were Compared With Measurements Obtained at Post-op Month 36
Difference in change in Z scoreNT-501 ImplantSham Surgery
Mean Change in Cone Spacing in Arcminutes (Z Score) of 2 Baseline Values Were Compared With Measurements Obtained at Post-op Month 361.13 ± 1.030.85 ± 1.78
SecondaryDifference in logMAR Visual Acuity Change Between CNTF- and Sham Treated Eyes

Difference in change in logMAR visual acuity between NT-501 and contralateral sham-treated eyes. Change in visual acuity was measured based on the number of letters read on a vision chart using a standard protocol. The log of the mean angle of resolution (logMAR) was used to describe the size of the smallest letters that the patient could read. A logMAR value of 0.00 corresponds to visual acuity of 20/20, a logMAR value of 0.3 corresponds to visual acuity of 20/40, a logMAR value of 0.7 corresponds to visual acuity of 20/100, and a logMAR value of 1.00 corresponds to visual acuity of 20/200.

Time frame:
Post-op Month 36
Reported as:
Mean · logMAR
Difference in logMAR Visual Acuity Change Between CNTF- and Sham Treated Eyes
logMARNT-501 ImplantSham Surgery
Difference in logMAR Visual Acuity Change Between CNTF- and Sham Treated Eyes0.004 ± 0.0100.014 ± 0.082

Adverse events

Collected over Serious and Other (Not Including Serious) Adverse Events were collected only for randomized participants through study completion, an average of 36 months. However, mortality is noted for one participant who passed away due to unrelated issues before being randomized.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NT-501 Implant0/22 (0%)4/22 (18.2%)2/22 (9.1%)
Sham Surgery0/22 (0%)4/22 (18.2%)1/22 (4.5%)
Prior to Randomization1/1 (100%)——
Most frequent serious events
Most frequent serious events
EventNT-501 ImplantSham SurgeryPrior to Randomization
Total Eye DisordersEye disorders4/221/22—
PregnancyPregnancy, puerperium and perinatal conditions1/221/22—
Reversible Cardiac VasospasmCardiac disorders1/221/22—
Clinically Significant Cystoid Macular EdemaEye disorders1/220/22—
Secondary Surgical Intervention (excluding Posterior Capsulotomy)Eye disorders1/221/22—
Ocular discomfortEye disorders1/220/22—
Reduced peripheral visual fieldEye disorders1/220/22—
Most frequent other events
Most frequent other events
EventNT-501 ImplantSham SurgeryPrior to Randomization
Epiretinal membraneEye disorders1/220/22—
Pelvic fractureMusculoskeletal and connective tissue disorders1/221/22—

Baseline characteristics

44 eyes of 22 patients were randomized to receive either NT-501 implant or sham surgery.

Age, Continuous
Age, Continuous(Years)NT-501 ImplantSham SurgeryTotal
Mean39.8 ± 11.939.8 ± 11.939.8 ± 11.9
Sex: Female, Male
Sex: Female, Male(Eyes)NT-501 ImplantSham SurgeryTotal
Female9918
Male131326
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Eyes)NT-501 ImplantSham SurgeryTotal
Hispanic or Latino224
Not Hispanic or Latino202040
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Eyes)NT-501 ImplantSham SurgeryTotal
American Indian or Alaska Native112
Asian224
Native Hawaiian or Other Pacific Islander112
Black or African American000
White181836
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Eyes)NT-501 ImplantSham SurgeryTotal
United States222244
09

Study locations

1 site
  • University of California, San Francisco
    San Francisco, California 94143, United States
10

References and documents

Publications

  • Duncan JL, Zhang Y, Gandhi J, Nakanishi C, Othman M, Branham KE, Swaroop A, Roorda A. High-resolution imaging with adaptive optics in patients with inherited retinal degeneration. Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3283-91. doi: 10.1167/iovs.06-1422. PubMed 17591900 ↗
  • Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, Bush RA. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3896-901. doi: 10.1073/pnas.0600236103. Epub 2006 Feb 27. PubMed 16505355 ↗
  • Talcott KE, Ratnam K, Sundquist SM, Lucero AS, Lujan BJ, Tao W, Porco TC, Roorda A, Duncan JL. Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment. Invest Ophthalmol Vis Sci. 2011 Apr 6;52(5):2219-26. doi: 10.1167/iovs.10-6479. PubMed 21087953 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Jul 2019 and a completion of Jul 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2023, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2012
First posted
Feb 10, 2012
Start
Jan 2012
Primary completionActual
Jul 1, 2019
CompletionActual
Jul 1, 2019
Results first posted
Feb 14, 2023
Last update
Feb 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01530659
Lead sponsor
Neurotech Pharmaceuticals
Responsible party
Sponsor
First posted
Feb 10, 2012
Start date
Jan 2012
Primary completion
Jul 1, 2019
Completion
Jul 1, 2019
Results posted
Feb 14, 2023
Last update
Feb 14, 2023

Study contacts

Jacque Duncan, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciliary Neurotrophic Factor

Start the discussion